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The binding of i4C-labelled tuberactinomycin 0 was analysed in equilibrium dialysis cells. The ionic condi- 
tions and the concentration of the labelled drug used in the binding assays allowed the binding of just one 
drug molecule per non-programmed ribosome. Under these conditions, the occupation of the ribosomal 
P-site by deacylated tRNAP” in the presence. of poly(U) increased the amount of [%]tuberactinomycin 0 
bound by a factor of two. Kanamycin, gentamicin and neomycin reduced the binding of tuberactinomycin 
0, whereas chloramphenicol, tetracycline, streptomycin and puromycin had no effect. A stimulation of the 
binding of tuberactinomycin 0 was found upon addition of erythromycin. 
Tuberactinomycin 0 binding Protein synthesis inhibitor Equilibrium dialysis Ribosomal tRNA binding 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
Viomycin (= tuberactinomycin B) is a peptide 
antibiotic which inhibits polypeptide synthesis in 
cultures of Mycobacterium avium [I], and in the 
cell-free systems of both Escherichia coli [2] and 
Mycobacterium smegmatis [3]. The drug blocks 
the translocation reaction [4,5], reduces tRNA 
binding to the ribosomal A-site and severely im- 
pairs the accuracy of tRNA selection at the A-site 
M. 
2.1. Antibiotics and reagents 
It is likely that the effect on ribosomal function 
involves a concerted action of both subunits, since 
it was found that resistance against viomycin could 
be conferred by an altered rRNA either in the 30 S 
or in the 50 S subunit [3,7]. This view is supported 
by the finding that viomycin favours the associa- 
tion and inhibits the dissociation of the subunits 
WI * 
Crude tuberactinomycin 0 was a gift from Toyo 
Jozo Co. It was purified by the procedure in [9]. 
Gentamicin (a mixture of Cla and C2) was a gift 
from Dr A. Bock (Universitat Munchen). 
Neomycin and puromycin were purchased from 
Sigma, Heidelberg, and kanamycin, poly(U), and 
tRNAPhe were from Boehringer, Mannheim. 
[14C]Urea (55 mCi/mmol, 887 pCi/mg) was ob- 
tained from the Radiochemical Centre, Amer- 
sham, England. 
2.2. Strain, culture media and ribosomes 
Here we demonstrate that the binding of 
[ “C]tuberactinomycin 0 to ribosomes is 
significantly enhanced by tRNA binding to the 
ribosomal P-site. Furthermore, binding of the 
drug was reduced by kanamycin, gentamicin and 
neomycin, whereas treptomycin, chloramphenicol 
and tetracycline had no effects. 
E. coli K12, strain A19, was cultured in 1% bac- 
totryptone (Difco), 0.5% yeast extract (Difco), 
0.09 M NaCl, 0.01 N NaOH and 0.2% glucose. 
Ribosomes (tight couples) were prepared as in [lo]. 
2.3. Preparation of [‘4C’tuberactinomycin 0
[14C]Tuberactinomycin 0 was prepared by in- 
cubating 3.75 mg tuberactinomycin 0 and 1 mCi 
[14C]urea in 75 pl of 3 N HCI at room temperature 
for 3 days, followed by purification on a Sephadex 
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G-10 column. The purity of the labelled antibiotic 
was checked by thin-layer chromatography on 
silica gel, using a solvent system consisting of 
acetone, 10% ammonium acetate, and ammonia in 
the ratio 10: 9: 1. The [‘4C]tuberactinomycin 0
thus obtained was used in concentrations of 
1.9 nmol/pl and 14 cpm/pmol. 
2.4. Equilibrium dialysis 
Equilibrium dialysis was carried out with cells 
containing two chambers each with a volume of 
200 ~1 as described [l 11. The dialysis was per- 
formed in the presence of 50 mM Tris-HCl (pH 
7.5), 10 mM Mg-acetate, 160 mM NH&I, 6.7 mM 
mercaptoethanol. One chamber contained 144- 
180 pmol ribosomes in 100 ~1, the other chamber 
1700 pmol [‘4C]tuberactinomycin 0 in the same 
volume. The equilibrium cells were gently shaken 
at 4°C for 19-24 h, then 2 x 40~1 aliquots were 
withdrawn with a syringe from each chamber and 
counted in a scintillation counter. The mean values 
of the two aliquots were calculated. From the dif- 
ference in the values found for the two chambers 
the amount of [14C]tuberactinomycin 0 bound to 
ribosomes was calculated. Where indicated, the 
ribosome chamber contained 75 pg (1.5 A260 units) 
of poly(U) and tRNAPhe as given in the tables. 
3. RESULTS AND DISCUSSION 
The binding of [‘4C]tuberactinomycin 0 to 
ribosomes was measured by equilibrium dialysis 
under conditions which yield the binding of one 
drug molecule per ribosome (see table 1, first line, 
182 pmol tuberactinomycin bound per 180 pmol 
ribosomes). The binding was stimulated by adding 
increasing amounts of deacylated tRNAPhe in the 
presence of the message poly(U). At a two-molar 
excess of tRNA the stimulation was more than 
two-fold. When poly(U) was omitted the addition 
of deacylated tRNA did not induce a significant 
effect. 
In the absence of ribosomes poly(U) alone 
showed some low binding of the antibiotic whereas 
with tRNAPhe no binding was found (see controls 
in table 1). The relatively low binding of tuber- 
actinomycin to nucleic acids observed here is due 
to the higher ionic strength we applied in these 
equilibrium dialysis experiments in contrast to the 
previous data [12]. Increasing the ionic strength 
Table 1 
Binding of [14C]tuberactinomycin 0 to ribosomes in the presence of various amounts of 
tRNAPhe 
Ribosomes 
(180 pmol) 
+ 
+ 
+ 
+ 
EolYw) Added Bound Relative binding 
tRNAPhe tuberactinomycin 0 
(pmol) (pmol) % (drug/70 S) 
+ 0 182 100 (1.00) 
+ 150 319 175 (1.75) 
+ 375 404 222 (2.22) 
+ 750 428 235 (2.35) 
+ - 0 193 106 (1.06) 
+ - 150 205 113 (1.13) 
+ - 375 247 136 (1.36) 
+ - 750 234 129 (1.29) 
Controls 
- + 0 127 69 
- - 0 0 0 
- - 150 0 0 
- - 375 0 0 
- - 750 0 0 
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dramatically reduces the binding of tuberactino- 
mycin to nucleic acids [ 121. 
Maximal stimulation of the binding of tuberac- 
tinomycin to programmed ribosomes was achieved 
by the addition of a two-molar excess of tRNAPhe 
(375 pmol tRNAPhe, see table 1). At this molar 
ratio tRNAPhe binds exclusively to the ribosomal 
P-site [13]. The addition of more tRNA does not 
further increase the drug binding (table 1, cf. bind- 
ing of 2.22 and 2.35 drug molecules per ribosome 
at the addition of 375 and 750 pmol tRNAPhe, 
respectively). 
The strikingly enhanced drug binding in the 
presence of tRNA suggests that tRNA binding to 
the P-site of programmed ribosomes may alter the 
ribosomal conformation or, alternatively, the 
presence of tRNA at the P-site stabilizes a defined 
conformational state which now represents an 
enlarged fraction of the ribosome population. Our 
finding is in accord with the observation of an in- 
creased ribosomal affinity for chloramphenicol 
and anisomycin, if the ribosomes bear a peptidyl 
tRNA at the P-site [14,15]. 
In the next experiments we compared the bind- 
ing of tuberactinomycin 0 with an excess of 
various other antibiotics. Table 2 demonstrates 
that kanamycin, gentamicin and neomycin were 
able to compete with the binding of tuberac- 
tinomycin 0 when tRNAPhe was bound to the P- 
site of programmed ribosomes. Erythromycin 
stimulated the binding of tuberactinomycin 0 even 
further, whereas the other antibiotics tested 
(chloramphenicol, tetracycline, streptomycin, and 
puromycin) had no significant effect. The competi- 
tion of the first 3 drugs was less pronounced when 
poly(U) and tRNAPhe were omitted from the assays 
(see table 2), and the stimulating effect of 
erythromycin was even reversed, leading to a slight 
depression. It is clear that A-site specific an- 
tibiotics such as tetracycline, streptomycin, 
chloramphenicol and puromycin had no effect on 
the binding of tuberactinomycin 0. Even the fill- 
ing of the A-site with N-acetyl-tRNAPhe did not in- 
fluence the binding of tuberactinomycin 0 (not 
shown). Thus, tRNA present at the ribosomal P- 
site stimulates the binding of tuberactinomycin 0 
but, on the other hand, ligands of the ribosomal A 
site do not interfere with the binding of tuberac- 
tinomycin. It is therefore evident that the binding 
site of tuberactinomycin 0 is located neither at the 
ribosomal P- nor at the ribosomal A-site, but is 
allosterically linked to the ribosomal P-site. 
Table 2 
Effect of various antibiotics on the binding of [‘4C]tuberactinomycin 0 to ribosomes 
Antibiotic added (uM) Tuberactinomycin 0 bound to Tuberactinomycin 0 bound to 
programmed 70 S non-programmed 70 S 
pm01 Relative binding pm01 Relative binding 
% (drug/70 S) % (drug/70 S) 
None - 330 100 (2.3) 200 100 (1.4) 
Kanamycin A 165 204 62 (1.4) 186 93 (1.3) 
Gentamicin C 170 202 61 (1.4) 161 81 (1.1) 
Neomycin B 130 187 57 (1.3) 178 89 (1.2) 
Chloramphenicol 250 353 107 (2.5) 197 99 (1.4) 
Tetracycline 180 309 94 (2.2) 190 95 (1.3) 
Streptomycin 140 351 106 (2.4) 211 106 (1.5) 
Puromycin 170 363 113 (2.5) 197 99 (1.4) 
Erythromycin 110 451 137 (3.1) 153 77 (1.1) 
The [‘4C]tuberactinomycin 0 concentration was 8.5 pM (1700 pmol per assay); ‘programmed 70 S’ means 
that 144 pmol of 70 S ribosomes were preincubated with 75 pg poly(U) (1.5 A260 units) and 300 pm01 
tRNAPhe (per assay); ‘non-programmed 70 S’ means that 144 pm0170 S ribosomes were present per assay 
without poly(U) or tRNAPh’ 
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